Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - los agentes quelantes de hierro - deferasirox mylan está indicado para el tratamiento de la sobrecarga férrica crónica debida a transfusiones sanguíneas frecuentes (≥7 ml/kg/mes de concentrado de hematíes) en pacientes con beta talasemia mayor, de edad de 6 años y olderthe tratamiento de la sobrecarga férrica crónica debida a transfusiones de sangre cuando el tratamiento con deferoxamina está contraindicado o no sea adecuado en los siguientes grupos de pacientes:en pacientes pediátricos con beta talasemia mayor con sobrecarga de hierro debida a transfusiones sanguíneas frecuentes (≥7 ml/kg/mes de concentrado de hematíes) de 2 a 5 años,en pacientes adultos y pediátricos con beta talasemia mayor con sobrecarga de hierro debida a transfusiones de sangre poco frecuentes (.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agentes antitrombóticos - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - bloqueo neuromuscular - todos los demás productos terapéuticos - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - la esclerosis múltiple remitente-recurrente - inmunosupresores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - escitalopram oxalato - comprimido recubierto con pelÍcula - 10 mg - escitalopram oxalato 10 mg - escitalopram

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - escitalopram oxalato - comprimido recubierto con pelÍcula - 15 mg - escitalopram oxalato 15 mg - escitalopram

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - escitalopram oxalato - comprimido recubierto con pelÍcula - 20 mg - escitalopram oxalato 20 mg - escitalopram

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - escitalopram oxalato - excipientes: croscarmelosa sodica - antidepresivos - inhibidores selectivos de la recaptación de serotonina - escitalopram